Committee Democrats Seek Documents From Gilead on HIV Prevention Drug
Washington, D.C. (June 27, 2019)— Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, Rep. Ro Khanna, Rep. Alexandria Ocasio-Cortez, and Rep. Ayanna Pressley sent a letter to Gilead Sciences seeking information about patents held by the federal government for the HIV prevention therapy known as Truvada for pre-exposure prophylaxis (PrEP).
“Gilead has taken the position that the government’s patents are not valid,” the Members wrote. “We would like to understand whether these patents played any role in the negotiations between the company and the Department of Health and Human Services (HHS), and whether Gilead has otherwise engaged in negotiations with the U.S. government regarding these patents.”
During the hearing, expert witnesses testified about the critical role played by the federal government—and the American taxpayers—in funding the research that led to PrEP and its patents registered by the Centers for Disease Control and Prevention.
Gilead charges approximately $2,000 per month for Truvada, while generic PrEP is available for as little as $210 per month in other countries.
The Members requested that the company produce these documents by July 25, 2019.
Click here to read the letter.